The effects of febuxostat and allopurinol castration–resistant prostate cancer cells using CD44 as an indicator: possibility for the drug repurposing of febuxostat in castration–resistant prostate cancer
Authors: Yasuhiro Suzuki1, et al.
+ View Affiliations
Source: Therapeutic Research Volume 44, Issue 5, 363 - 368 (2023)
Publisher: ライフサイエンス出版
Abstract
Drug repurposing, is the re–tasking of known medications for new clinical indications. In this in vitro study, we evaluated the possibility of the drug repurposing of xanthine oxidase inhibitors (febuxostat and allopurinol) for treating castration–resistant prostate cancer. We used the castration–resistant prostate cancer cell line PC–3 to investigate the effect of xanthine oxidase inhibitors on the production of CD44, an adhesion factor and cancer stem cell marker. The CD44 mRNA expression levels were then evaluated by a real–time PCR. The results demonstrated that the application of febuxostat caused a concentration–dependent inhibition of the expression levels of CD44; a significant suppression occurred with the 100 μM concentration. The 15–min application of febuxostat without TNF–α treatment significantly suppressed CD44 mRNA and protein expression 24 hours after the 100 μM febuxostat treatment. The pretreatment with allopurinol did not decrease the expression of CD44 mRNA and protein expression without TNF–α. The production of CD44 in PC3 cells was suppressed by febuxostat treatment in this experiment, indicating a possibility for the repositioning of febuxostat.